Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
Telomir Pharmaceuticals (NASDAQ:TELO) executed a binding LOI to acquire TELI Pharmaceuticals and consolidate worldwide rights to Telomir-1, converting each TELI share into TELO stock with an exchange ratio set by independent valuation. The deal includes up to $5 million in potential shareholder contributions: $1M at closing, $2M on IND acceptance, $2M at Phase 1/2 start. Closing is subject to shareholder approval, regulatory and diligence conditions; TELI shareholders face a six-month lockup. Telomir-1 has multiple preclinical signals across oncology, AMD, metabolic and aging models, and unified rights aim to enable global partnerships and out-licensing across larger ex-U.S. markets.
Telomir Pharmaceuticals (NASDAQ:TELO) ha eseguito una LOI vincolante per acquisire TELI Pharmaceuticals e consolidare diritti mondiali su Telomir-1, convertendo ogni azione TELI in azioni TELO con un rapporto di cambio stabilito da una valutazione indipendente. L accordo prevede fino a 5 milioni di dollari in potenziali contributi degli azionisti: 1 M$ al closing, 2 M$ all accettazione dell IND, 2 M$ all inizio della fase 1/2. Il closing è soggetto all'approvazione degli azionisti, a condizioni regolatorie e di due diligence; gli azionisti TELI affrontano una lockup di sei mesi. Telomir-1 presenta numerosi segnali preclinici in modelli di oncologia, AMD, metabolici e di invecchiamento, e i diritti unificati mirano a facilitare partnership globali e licensing out nei mercati esteri di maggiori dimensioni.
Telomir Pharmaceuticals (NASDAQ:TELO) ejecutó una LOI vinculante para adquirir TELI Pharmaceuticals y consolidar derechos mundiales sobre Telomir-1, convirtiendo cada acción de TELI en acciones TELO con una relación de intercambio determinada por una valoración independiente. El acuerdo incluye hasta $5 millones en posibles aportes de accionistas: $1M al cierre, $2M al aceptar el IND, $2M al inicio de la fase 1/2. El cierre está sujeto a la aprobación de los accionistas, condiciones regulatorias y de diligencia; los accionistas de TELI enfrentan un lockup de seis meses. Telomir-1 tiene múltiples señales preclínicas en oncología, AMD, modelos metabólicos y de envejecimiento, y los derechos unificados buscan facilitar asociaciones globales y licensing externo en mercados ex-U.S. más grandes.
텔로미르 파마슈티컬스(NASDAQ:TELO)는 TELI Pharmaceuticals를 인수하고 Telomir-1에 대한 전 세계 권리를 통합하기 위한 구속력 있는 LOI를 체결했으며, TELI 주식을 TELO 주식으로 교환하는 비율은 독립적인 평가에 의해 결정됩니다. 거래에는 주주 기여금으로 최대 $5백만까지 포함되며: 종가 시점 1백만 달러, IND 승인 시 2백만 달러, 1/2상 시작 시 2백만 달러가 포함됩니다. 마감은 주주 승인, 규제 및 실사 조건에 따라 달라지며 TELI 주주는 6개월 락업에 직면합니다. Telomir-1은 종양학, AMD(연령 관련 황반변성), 대사 및 노화 모델에서 다수의 전임상 신호를 보유하고 있으며, 통합 권리는 글로벌 파트너십 및 미국 외 대형 시장에서의 라이선스 아웃을 가능하게 하는 것을 목표로 합니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a signé une LOI contraignante pour acquérir TELI Pharmaceuticals et consolider les droits mondiaux sur Telomir-1, en convertissant chaque action TELI en actions TELO selon un ratio d échange établi par une évaluation indépendante. L accord prévoit jusqu à 5 millions de dollars de contributions potentielles des actionnaires : 1 M$ à la clôture, 2 M$ lors de l acceptation de l IND, 2 M$ au démarrage de la phase 1/2. La clôture est subordonnée à l approbation des actionnaires, aux conditions réglementaires et de diligence; les actionnaires de TELI font face à un verrouillage de six mois. Telomir-1 présente de multiples signaux précliniques dans des modèles d oncologie, de DMLA (AMD), métaboliques et de vieillissement, et les droits unifiés visent à faciliter des partenariats mondiaux et des licences externes sur des marchés ex-US plus importants.
Telomir Pharmaceuticals (NASDAQ:TELO) hat eine verbindliche LOI zur Übernahme von TELI Pharmaceuticals abgeschlossen und weltweite Rechte an Telomir-1 konsolidiert, wobei jeder TELI-Aktie in TELO-Aktien zu einem Verhältnis umgewandelt wird, das durch eine unabhängige Bewertung festgelegt ist. Die Vereinbarung umfasst bis zu 5 Millionen Dollar an potenziellen Beiträgen der Aktionäre: 1 Mio. $ bei Abschluss, 2 Mio. $ bei Zulassung des IND, 2 Mio. $ zu Beginn der Phase 1/2. Der Abschluss unterliegt der Zustimmung der Aktionäre, regulatorischen und Due-Diligence-Bedingungen; TELI-Aktionäre sehen sich einer Sechs-Monats-Lockup gegenüber. Telomir-1 weist mehrere präklinische Signale in Onkologie, AMD, metabolischen und Alterungsmodellen auf, und die einheitlichen Rechte zielen darauf ab, globale Partnerschaften und Licensing-Out auf größeren außer-US-Märkten zu ermöglichen.
Telomir Pharmaceuticals (NASDAQ:TELO) نفذت خطاب نوايا ملزم لشراء TELI Pharmaceuticals وتوحيد حقوق Telomir-1 عالميًا، مع تحويل كل سهم TELI إلى أسهم TELO وفق نسب تبادل تحددها تقييم مستقل. يتضمن الاتفاق حتى 5 ملايين دولار من المساهمات المحتملة للمساهمين: 1 مليون دولار عند الإغلاق، 2 مليون دولار عند قبول IND، 2 مليون دولار عند بدء المرحلة 1/2. الإغلاق خاضع لموافقة المساهمين والقيود التنظيمية وشروط التدقيق؛ يواجه مساهمو TELI قيد قفل لمدة ستة أشهر. لدى Telomir-1 إشارات ما قبل السريرية متعددة عبر علم الأورام وAMD والعمليات الأيضية ونماذج الشيخوخة، وتُهدف الحقوق الموحدة إلى تمكين شراكات عالمية والترخيص الخارجي في أسواق خارج الولايات المتحدة الأوسع.
Telomir Pharmaceuticals (NASDAQ:TELO) 已签署一项具约束力的意向书，以收购 TELI Pharmaceuticals 并整合 Telomir-1 的全球权利，将 TELI 的每股转换为 TELO 股票，换股比例由独立评估确定。交易包含最多 500万美元 的潜在股东出资：交割时1百万美元、IND 批准时2百万美元、1/2期开始时2百万美元。交割须经股东批准、并受监管及尽职调查条件约束；TELI 股东面临 六个月锁定期。Telomir-1 在肿瘤学、AMD、代谢和衰老模型方面有多项前临床信号，统一权利旨在促成全球伙伴关系与对外授权，以覆盖更大的美国以外市场。
- Consolidation of worldwide IP rights for Telomir-1
- Up to $5 million in milestone-tied shareholder contributions
- Stock-for-stock structure aligns stakeholders via independent valuation
- Preclinical activity across oncology, AMD, metabolic, and aging models
- Transaction requires shareholder approval and customary due diligence
- Milestone contributions are conditional and not guaranteed
- TELI shareholders subject to a six-month lockup on received shares
Insights
Binding LOI consolidates global IP for Telomir-1, adds up to
Business mechanism: The stock-for-stock LOI unifies U.S. and ex-U.S. intellectual property into a single owner, creating a cleaner legal and commercial holder for Telomir-1. That structure makes global partnering, regional licensing, or an asset sale administratively simpler and preserves optionality across oncology, metabolic, and age-related indications.
Dependencies and risks: Impact depends on successful shareholder approval and customary closing conditions, plus later technical milestones: IND acceptance and Phase 1/2 initiation trigger up to
What to watch (near–to–medium term): monitor shareholder vote timing and outcome, receipt of the
Unifying global IP rights and enabling up to
MIAMI, FLORIDA / ACCESS Newswire / October 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers of cancer, aging, and age-related disease, today announced that it has executed a binding Letter of Intent (the "LOI") to acquire TELI Pharmaceuticals, Inc., securing worldwide rights to its lead investigational therapy, Telomir-1.
The transaction aligns Telomir's U.S. rights with TELI's ex-U.S. intellectual property portfolio, which includes filings across Europe, Canada, Mexico, China, Japan, South Korea, India, Israel, Australia, Argentina, Uruguay, Taiwan, and the United Arab Emirates-creating a single global owner positioned to capture the full commercial value of Telomir-1 across oncology, metabolic, and age-related diseases.
Under the LOI, each outstanding share of TELI common stock will be exchanged for shares of TELO common stock, with the exchange ratio determined by an independent valuation. The transaction also includes up to
Why Worldwide Rights Expand Value
Global oncology spend is accelerating: Cancer medicine spending reached
$223 billion in 2023 and is projected to reach ~$409 billion by 2028; the U.S. represented roughly 45 percent ($99 billion in 2023) - meaning ex-U.S. markets now account for the majority of global oncology spend (IQVIA Global Oncology Trends 2024).Age-related and metabolic markets add further upside: The age-related macular degeneration (AMD) drug market totaled
$10.8 billion in 2023 and is projected to grow to ~$18 billion by 2030 (Grand View Research 2024). Meanwhile, the global economic cost of diabetes, dementia, and neurodegenerative disease exceeds$2 trillion annually and continues to rise (IDF Diabetes Atlas 2023; Alzheimer's Disease International 2023).Investor takeaway: With worldwide rights, Telomir can now pursue global or regional partnerships, out-licensing, or asset-sale opportunities across markets where ex-U.S. demand exceeds U.S. demand - enhancing strategic flexibility and long-term enterprise value.
CEO Commentary
Erez Aminov, Chief Executive Officer of the Company, stated:
"Executing this binding LOI to secure worldwide rights transforms Telomir-1 from a U.S.-focused asset into a global platform. Strategically, it gives us cleaner access to partnership, licensing, or even asset sale opportunities across continents. Economically, the addressable market outside the United States is larger than inside it. We believe this unified structure positions Telomir for significant long-term value creation as we continue advancing our epigenetic and longevity programs."
Dr. Itzchak Angel, Chief Scientific Advisor of the Company, added:
"This global alignment enables us to plan development for true worldwide impact. It streamlines our path to explore Telomir-1 in oncology, metabolic, and degenerative diseases such as breast and pancreatic cancer, AMD, Progeria, Wilson's disease, and Type 2 diabetes, where our preclinical data already show compelling functional restoration."
Scientific and Market Context
Telomir-1 is an investigational oral small-molecule epigenetic therapy designed to reset abnormal DNA methylation patterns, stabilize telomeres, and restore proper gene regulation - addressing the root biological causes of cancer, aging, and degenerative disease rather than their downstream symptoms.
Across multiple preclinical models, Telomir-1 has shown activity at the intersection of epigenetic control, DNA methylation balance, telomere maintenance, metal regulation, and mitochondrial health - five cellular processes central to both oncologic and age-related disorders.
Representative findings include:
Oncology:
In triple-negative breast (TNBC) and pancreatic cancer models, Telomir-1 produced a dose dependent loss of cancer-cell viability through iron-dependent mitochondrial and energy-pathway modulation.
In prostate cancer, Telomir-1 reversed abnormal DNA methylation of tumor suppressor genes MASPIN, RASSF1A, and STAT1, reactivating natural anti-metastatic defenses.
Age-Related Macular Degeneration (AMD): Telomir-1 restored retinal structure and vision in a validated zebrafish model, demonstrating neuroprotective and regenerative effects.
Progeria & Werner Syndrome: In patient-derived Progeria (HGPS) cells, Telomir-1 normalized oxidative stress and mitochondrial instability. In nematode and zebrafish models of Werner-like accelerated aging, it extended lifespan, lengthened telomeres, reversed muscle degeneration, and reset molecular-age markers.
Wilson's Disease: In a genetic ATP7B-deficient (C271X⁻/⁻) zebrafish model, Telomir-1 produced dose-dependent restoration of neurological, hepatic, and renal function, reducing tremors four- to five-fold, halving hepatic copper accumulation, reversing liver and kidney pathology, normalizing ALT, AST, and bilirubin, and improving survival under copper stress.
Type 2 Diabetes: In a zebrafish model of Type 2 diabetes mellitus, Telomir-1 reversed hyperglycemia and insulin resistance to near pre-diabetic levels, significantly reduced HOMA-IR values, improved oral glucose tolerance, and increased survival. Mechanistically, Telomir-1 appears to normalize iron metabolism and reduce oxidative stress in pancreatic beta cells, directly addressing the root cause of insulin resistance.
Longevity & Healthspan: Using microfluidic C. elegans aging models developed with Nagi Bioscience SA, Telomir-1 extended lifespan, improved mobility, and reversed biological age markers, confirming its potential to enhance both longevity and healthspan.
Collectively, these data position Telomir-1 as a potential first-in-class DNA methylation reset and telomere stabilizing therapy with multi-system regenerative potential.
From a commercial perspective, unifying worldwide rights enables Telomir to access multi-hundred-billion-dollar opportunities. Global oncology spending alone is projected to exceed
Key LOI Terms (Summary)
Structure: Stock-for-stock acquisition; exchange ratio determined by independent valuation.
Shareholder Contribution: A potential for up to
$5 million in cash or cash equivalents over the duration of the collaboration-$1 million at closing;$2 million upon IND acceptance;$2 million upon Phase 1/2 initiation. Milestone shares allocated but not issued until funded.Lockup: TELI shareholders subject to a six-month lockup on shares received.
Closing: Not contingent on milestone payments; subject to customary board, stockholder, regulatory, and due diligence conditions.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing small-molecule therapies that target epigenetic drivers of cancer, aging, and age-related disease. Its lead candidate, Telomir-1, has demonstrated the ability to reset DNA methylation, stabilize telomeres, inhibit histone demethylases, and restore cellular energy and metabolic balance across multiple preclinical models. For more information, visit www.telomirpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc
View the original press release on ACCESS Newswire
FAQ
What did Telomir (TELO) announce on October 21, 2025 regarding Telomir-1?
How much funding will TELI shareholders potentially contribute to TELO under the LOI?
Is the TELO-TELI transaction conditional or finalized?
What commercial advantage does Telomir expect from acquiring worldwide rights to Telomir-1?
Will TELI shareholders be restricted after the deal closes?
What preclinical evidence supports Telomir-1’s potential?
